Predicting treatment for sarcomas and melanomas using patient-derived models
Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)
This study is trying to see if creating models from tumor samples can help find the best drug combinations for patients with sarcomas and melanomas after their usual treatments haven't worked.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 21 Years to 99 Years |
| Sex | All |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Locations | 1 site (Singapore) |
| Trial ID | NCT04986748 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate drug sensitivities in patients with sarcomas and melanomas by creating two- and three-dimensional models from tumor samples. Patients will undergo standard-of-care resections or biopsies, which will be used to generate these models. The study will then perform ex vivo drug testing on these models using a panel of up to 14 drugs known to be effective against these cancers. The goal is to identify effective drug combinations and tailor treatments based on individual patient responses after standard treatments have failed.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with sarcoma or melanoma who have at least one tumor lesion suitable for biopsy or resection.
Not a fit: Patients who do not have a diagnosis of sarcoma or melanoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for patients with sarcomas and melanomas.
How similar studies have performed: While the approach of using patient-derived models for drug testing is gaining traction, this specific application of QPOP in sarcomas and melanomas is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of sarcoma or melanoma * At least 1 tumour lesion amenable to fresh biopsy or resection * Signed informed consent from patient or legal representative * Able to comply with study-related procedures Exclusion Criteria: * There are no specific exclusion criteria if patients meet the inclusion criteria
Where this trial is running
Singapore
- National Cancer Centre Singapore — Singapore, Singapore (Recruiting)
Study contacts
- Principal investigator: Valerie Shiwen Yang, BSc, MB BChir, PhD — National Cancer Centre, Singapore
- Study coordinator: Valerie Shiwen Yang, BSc, MB BChir, PhD
- Email: valerie.yang.s.w@singhealth.com.sg
- Phone: +65 6436 8088
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.